Alirocumab + Chemo for Lung Cancer

Overseen By Monika Anand, PhD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Duke University

Must not be taking: Anti-PD-1, Anti-PD-L1

Disqualifiers: EGFR mutations, Active TB, Autoimmune, others

Stay on Your Current Meds You can continue your current medications while participating

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 3

Duration: 9 weeks

126 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether adding alirocumab, a cholesterol-lowering drug, to a standard chemotherapy and cemiplimab combination can help the immune system target lung cancer cells more effectively before surgery. It targets individuals with non-small cell lung cancer (NSCLC) that can be surgically removed. Participants will receive either the standard treatment or the same treatment plus alirocumab to determine which is more effective. Suitable candidates include those with a lung cancer tumor 3 cm or larger who have not undergone previous cancer treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently receiving other anti-tumor therapies or have used an anti-PCSK9 agent within 90 days of the study. It's best to discuss your specific medications with the trial team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that alirocumab is generally safe and well-tolerated. Many studies have found that it significantly lowers LDL cholesterol levels when combined with statin therapy, without major safety issues. Importantly, further analysis found no increased risk of new or worsening cancers in people taking alirocumab.

Cemiplimab also has a strong safety record. Studies have demonstrated its safety for treating advanced non-small cell lung cancer, with patients responding well to the combination of cemiplimab and chemotherapy. This treatment has been used in other situations with a good safety profile.

In this trial, both alirocumab and cemiplimab are tested together with chemotherapy. Previous research supports their safety, but potential risks should be considered when joining any trial. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments because they combine chemotherapy and cemiplimab, a PD-1 inhibitor, with or without alirocumab, a PCSK9 inhibitor, for lung cancer. Cemiplimab works by unleashing the immune system to attack cancer cells, which is different from traditional chemotherapy that directly targets and kills cancer cells. The inclusion of alirocumab is particularly intriguing because it targets PCSK9, a protein usually associated with cholesterol regulation, but here it may also enhance the immune response against cancer. This dual approach could potentially improve outcomes by making cancer cells more vulnerable to the immune system while using chemo to shrink the tumor.

What evidence suggests that this trial's treatments could be effective for non-small cell lung cancer?

Research has shown that cemiplimab, when combined with chemotherapy, significantly improves survival rates in patients with advanced non-small cell lung cancer (NSCLC). Studies have found that cemiplimab, a drug that aids the immune system in fighting cancer, increases both overall survival and the time patients live without cancer progression compared to chemotherapy alone. Cemiplimab also provides a survival benefit over five years for NSCLC patients. In this trial, participants in Arm B will receive chemotherapy and cemiplimab every three weeks for three cycles without alirocumab before surgery. Meanwhile, participants in Arm A will receive chemotherapy and cemiplimab every three weeks for three cycles with alirocumab every four weeks before surgery. Alirocumab, typically used to lower cholesterol, is being tested to determine if it can help the immune system better recognize and attack cancer cells. Although research on alirocumab's effectiveness in lung cancer continues, early studies suggest it might enhance the immune response, potentially improving cancer treatment outcomes. ^{1 6 7 8 9}

Who Is on the Research Team?

Neal Ready, MD, PhD

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

Adults over 18 with a certain stage of lung cancer (NSCLC) that hasn't been treated yet. They must have a tumor at least 3 cm big, be in good physical shape, and considered able to undergo surgery. People who've had other cancers within the last two years or previous treatments for their lung cancer can't join.

Inclusion Criteria

I am fully active or can carry out light work.

I am considered fit for surgery.

Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1

Exclusion Criteria

I have a history of lung inflammation not caused by an infection.

I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.

Hypersensitivity to alirocumab or any of its excipients

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Neoadjuvant chemotherapy and cemiplimab every 3 weeks for 3 cycles with or without alirocumab every 4 weeks prior to surgery

9 weeks

3 visits (in-person)

Surgery

Surgical resection of the tumor following neoadjuvant therapy

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years

What Are the Treatments Tested in This Trial?

Interventions

• Alirocumab
• Cemiplimab

Trial Overview The trial is testing if adding Alirocumab to standard chemo and Cemiplimab before surgery helps more than just chemo and Cemiplimab alone in patients with NSCLC. Participants are randomly placed into one of the two groups to compare results.

How Is the Trial Designed?

Group I: Arm B Experimental Treatment 2 Interventions

Chemotherapy and cemiplimab (PD-1 inhibitor) every 3 weeks for 3 cycles without alirocumab (PCSK9 inhibitor) prior to surgery

Group II: Arm A Experimental Treatment 3 Interventions

Chemotherapy and cemiplimab (PD-1 inhibitor) every 3 weeks for 3 cycles with alirocumab (PCSK9 inhibitor) every 4 weeks prior to surgery

Cemiplimab is already approved in European Union, United States, Canada, Brazil for the following indications:

Approved in European Union as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)
• Non-small cell lung cancer (NSCLC)

Approved in United States as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)
• Basal cell carcinoma (BCC)
• Non-small cell lung cancer (NSCLC)

Approved in Canada as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)
• Non-small cell lung cancer (NSCLC)

Approved in Brazil as Libtayo for:

• Cutaneous squamous cell carcinoma (CSCC)

Who Is Running the Clinical Trial?

Duke University

Lead Sponsor

Trials

2,495

Recruited

5,912,000+

Regeneron Pharmaceuticals

Industry Sponsor

Trials

690

Recruited

948,000+

Founded

1988

Headquarters

Tarrytown, USA

Known For

Precision medicine

Top Products

Dupixent, EYLEA, Libtayo, Praluent

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School

Published Research Related to This Trial

Cemiplimab-rwlc (Libtayo) is an FDA-approved immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC) that works by blocking the PD-1 receptor, enhancing the immune system's ability to fight tumors.

Clinical trials have shown that cemiplimab is effective in treating CSCC, although common side effects and safety issues were noted, highlighting the need for ongoing research to improve treatment outcomes and reduce toxicity.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Ahmed, SR., Petersen, E., Patel, R., et al.[2019]

In the EMPOWER-Lung 3 study, patients with advanced non-small cell lung cancer (NSCLC) treated with cemiplimab plus chemotherapy had a median overall survival of 21.1 months compared to 12.9 months for those receiving chemotherapy alone, demonstrating a significant survival benefit after 28.4 months of follow-up.

Cemiplimab plus chemotherapy also resulted in improved progression-free survival (8.2 months vs. 5.5 months) and higher objective response rates (43.6% vs. 22.1%), although it was associated with a higher incidence of severe adverse events (48.7% vs. 32.7%).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. Makharadze, T., Gogishvili, M., Melkadze, T., et al.[2023]

In a phase 3 study involving 710 patients with advanced non-small-cell lung cancer and high PD-L1 expression, cemiplimab significantly improved overall survival (not reached) and progression-free survival (8.2 months) compared to chemotherapy (14.2 months).

Cemiplimab also demonstrated a better safety profile, with fewer grade 3-4 treatment-emergent adverse events (28%) compared to chemotherapy (39%), making it a promising first-line treatment option for this patient group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Sezer, A., Kilickap, S., Gümüş, M., et al.[2022]

Cemiplimab-rwlc is a newly approved PD-1/L1 inhibitor for first-line treatment of metastatic non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, either alone or with chemotherapy.

This review highlights the differences in patient populations studied for cemiplimab compared to other treatments, emphasizing its role in expanding options for NSCLC patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations. Ahn, J., Nagasaka, M.[2023]

This phase I/II clinical trial is investigating the safety and efficacy of a combination treatment involving selumetinib, tremelimumab, and durvalumab in 40 patients with previously treated, unresectable non-small-cell lung cancer (NSCLC).

The study aims to determine the maximum tolerated dose and progression-free survival, while also exploring biomarkers of response and resistance, which could help tailor future treatments for NSCLC patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Gaudreau, PO., Lee, JJ., Heymach, JV., et al.[2021]

Cemiplimab, administered as monotherapy or in combination with hypofractionated radiation therapy, showed a 10% objective response rate in patients with recurrent or metastatic cervical cancer, particularly in those with squamous histology, indicating its potential efficacy in this subgroup.

The most common side effects were diarrhea, fatigue, and hypokalemia, affecting 35%, 25%, and 25% of patients respectively, suggesting that while cemiplimab has anti-tumor activity, it also has a manageable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Rischin, D., Gil-Martin, M., González-Martin, A., et al.[2021]

In the EMPOWER-Lung 1 trial, cemiplimab significantly improved overall survival compared to platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression (≥50%).

Patients receiving cemiplimab reported better quality of life and functioning, with a lower risk of definitive deterioration in symptoms such as dyspnea, cough, and fatigue, indicating that cemiplimab not only extends survival but also enhances the patient's overall well-being.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study. Gümüş, M., Chen, CI., Ivanescu, C., et al.[2023]

At 35 months of follow-up, patients with advanced non-small-cell lung cancer and high PD-L1 expression treated with cemiplimab had a median overall survival of 26.1 months, significantly better than the 13.3 months for those receiving chemotherapy, indicating a strong survival benefit from cemiplimab.

The addition of chemotherapy to cemiplimab after disease progression resulted in a median overall survival of 15.1 months, suggesting that this combination could be an effective second-line treatment option for patients with advanced non-small-cell lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Özgüroğlu, M., Kilickap, S., Sezer, A., et al.[2023]

In patients with advanced non-small-cell lung cancer (NSCLC) and high PD-L1 expression (≥50%), cemiplimab showed significant improvements in progression-free survival (PFS) and objective response rate (ORR) compared to pembrolizumab, based on a systematic review and network meta-analysis of randomized-controlled trials.

Cemiplimab demonstrated comparable overall survival (OS) and similar safety profiles to pembrolizumab, indicating it is a viable first-line treatment option for this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50. Freemantle, N., Xu, Y., Wilson, FR., et al.[2022]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10547267/

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab ... Thus, alirocumab appears to be a safe, well‐tolerated, and effective lipid‐modifying and outcome‐improving treatment when used for up to 5 years ...

2. pharmaceutical-technology.com pharmaceutical-technology.com/data-insights/alirocumab-sanofi-non-small-cell-lung-cancer-likelihood-of-approval/

Alirocumab by Sanofi for Non-Small Cell Lung Cancer According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for ...

3. sciencedirect.com sciencedirect.com/science/article/pii/S075333222301689X

Advances and challenges in the treatment of lung cancer Experimental results revealed that NI/HA-DDP-LPNs exhibited excellent anti-tumor effects against drug-resistant human lung cancer A549/DDP cells ...

4. withpower.com withpower.com/trial/phase-2-lung-neoplasms-6-2024-526ae

Alirocumab + Chemo for Lung Cancer Research shows that cemiplimab, when combined with chemotherapy, improved survival in patients with advanced non-small cell lung cancer compared to chemotherapy ...

5. journal-of-cardiology.com journal-of-cardiology.com/article/S0914-5087(18)30295-8/fulltext

Efficacy and safety of alirocumab 150 mg every 4 weeks in ... Alirocumab 150mg Q4W (with up-titration to Q2W in 49.1% of patients) produced a 51.7% reduction in LDL-C from baseline, 63.9% of patients ...

6. clinicaltrials.gov clinicaltrials.gov/study/NCT01623115

NCT01623115 | Efficacy and Safety of Alirocumab ... To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10501297/

A pooled, post hoc, competing risk analysis of alirocumab ... This post hoc analysis assessed the risk of new and worsening cancers among participants who received the PCSK9 inhibitor alirocumab, using ...

8. clinicaltrials.gov clinicaltrials.gov/study/NCT01288443

Study Details | NCT01288443 | Efficacy and Safety ... To evaluate the safety and tolerability of alirocumab; To evaluate the development of anti-alirocumab antibodies; To evaluate the pharmacokinetics of alirocumab.

9. nejm.org nejm.org/doi/full/10.1056/NEJMoa1501031

Efficacy and Safety of Alirocumab in Reducing Lipids and ... Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels.